We’re excited to announce that for a second time in a row, based on positive survey results from our employees, we have been awarded a “World-class Workplace” for 2024-2025 by Effectory! We are grateful for everyone that makes Merus as a great place to work! #CloseInOnCancer
Merus N.V.
Biotechnologisch onderzoek
Utrecht, Utrecht 11.652 volgers
Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c
Over ons
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/
- Website
-
http://www.merus.nl
Externe link voor Merus N.V.
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 201 - 500 medewerkers
- Hoofdkantoor
- Utrecht, Utrecht
- Typ
- Naamloze vennootschap
- Specialismen
- immuno-oncology, oncology, immunology, antibody engineering, antibody discovery, cell biology, In vivo, biomarker development, early discovery, protein production, robotics en functional assays
Locaties
-
Primair
Yalelaan 62
Utrecht, Utrecht 3584 CM, NL
-
1 Broadway
Cambridge, MA 02142, US
Medewerkers van Merus N.V.
Aktualisierungen
-
Joeffrey Chahine, PhD, Technical Director Molecular Diagnostics Laboratory, describes the evolution of genomic testing and shares his thoughts on RNA-based next-generation sequencing. Find out more at https://bit.ly/4eWnQY5 #PrecisionOncology #FindTheFusions #PrecisionMedicine
-
At Merus, Shekeab is involved in designing clinical trials and moving cancer drug candidates through the phases of development. It is a cross-functional role where he collaborates with many departments to reach our goal of #CloseInOnCancer #JoinTheMerusMission Learn more about his journey>> https://lnkd.in/eSxTq9SR
-
Mary joined Merus in 2021 seeking a workplace that prioritizes a positive environment. Mary values the camaraderie and teamwork at Merus, which fosters a productive and supportive atmosphere. #CloseInOnCancer #JoinTheMerusMission Read more: https://lnkd.in/ejQjYHyg
-
Comprehensive testing with RNA-based NGS, including DNA and RNA sequencing, is recommended to capture what DNA-based NGS alone can miss. Find out more at bit.ly/3W6SWFe #PrecisionOncology #FindTheFusions #PrecisionMedicine
-
Bill Lundberg, MD, Merus’ CEO, will present today at Canaccord Genuity’s 44th Annual Growth Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CGDriven #DrivenByYourSuccess #CloseInOnCancer
-
At Merus, Loes found an impressive mix of people in terms of age, experience, and cultural background – all striving for the same goal – to #CloseInOnCancer Learn more about Loes journey: https://lnkd.in/esS9GPme
-
Eric started out at Merus as an IT contractor. It turned out to be such a great experience, he decided to stick around and has held numerous roles with increasing responsibilities. Eric finds Merus to be an organization with a clear purpose and a compelling mission. #CloseInOnCancer #JoinTheMerusMission https://lnkd.in/exAyaKvZ
-
Studies observed that tumors driven by NRG1 fusions possess aggressive histological features and are reported as associated with poor prognosis and shorter overall survival in lung cancer. Learn more at https://bit.ly/45IN0Fk. #PrecisionOncology #FindTheFusions #PrecisionMedicine #LungCancer
-
Linda joined Merus in 2016. We’ve grown significantly since that time, but our mission hasn’t changed. Step by step, we are closing in on cancer every day. Learn more about Linda’s journey: https://lnkd.in/eg8822XM #CloseInOnCancer #JoinTheMerusMission
Vergelijkbare pagina’s
Door vacatures bladeren
Financiering
Laatste ronde
Vermogen na beursgangUS$ 400.200.000,00